## Edgar Filing: Kogan Yakov - Form 4

Kogan Yakov Form 4										
June 15, 2012										
FORM 4	1						E COMMISSIO		PPROVAL	
	N OMB Number:	3235-0287								
Check this box if no longer									January 31, 2005	
subject to Section 16. Form 4 or							Estimated burden ho response	average urs per		
Form 5 obligations may continue <i>See</i> Instruction 1(b).	Section 17(	a) of the	Public U	Jtility Ho	olding Co		ange Act of 1934, t of 1935 or Secti 1940			
(Print or Type Resp	onses)									
1. Name and Address of Reporting Person <u>*</u> Kogan Yakov			2. Issuer Name <b>and</b> Ticker or Trading Symbol CLEVELAND BIOLABS INC			5. Relationship of Reporting Person(s) to Issuer				
		[CBLI]				(Check all applicable)				
(Last) (First) (Middle) C/O CLEVELAND BIOLABS, INC., 73 HIGH STREET			3. Date of Earliest Transaction (Month/Day/Year) 06/13/2012			X Director 10% Owner X Officer (give title Other (specify below) below) Chief Executive Officer				
n(e., / 5 mon	(Street)		4 If Am	andmant I	Data Origin	-1	6 Individual or	Joint/Group Fili	ng(Chaok	
	4. If Amendment, Date Original Filed(Month/Day/Year)			<ul> <li>6. Individual or Joint/Group Filing(Check</li> <li>Applicable Line)</li> <li>_X_ Form filed by One Reporting Person</li> <li> Form filed by More than One Reporting</li> </ul>						
BUFFALO, NY	14203						Person			
(City)	(State)	(Zip)	Tab	ole I - Non	-Derivative	e Securities	Acquired, Disposed	of, or Beneficia	lly Owned	
1.Title of Security (Instr. 3)2. Transaction Date (Month/Day/Year)2A. Deeme Execution I any (Month/Day/Year)			Date, if TransactionAcquired (A) or Code Disposed of (D) ay/Year) (Instr. 8) (Instr. 3, 4 and 5) (A)			(A) or of (D) 4 and 5) (A)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
	or Code V Amount (D) Price				e (Instr. 3 and 4)					
Reminder: Report of	on a cenarate line	o for each cl	ass of sec	urities ben	eficially ou	uned directly	or indirectly			
reminer: report	n a separate ma				Perso infor requi	ons who re mation con red to resp ays a curre	espond to the collected stained in this form bond unless the fo ently valid OMB co	n are not rm	SEC 1474 (9-02)	
	Tab					sposed of, or convertible	r Beneficially Owned securities)	d		

1. Title of	2.	3. Transaction Date	3A. Deemed	4.	5. Number of	6. Date Exercisable and	7. Title and Amount of
Derivative	Conversion	(Month/Day/Year)	Execution Date, if	Transacti	orDerivative	Expiration Date	Underlying Securities

## Edgar Filing: Kogan Yakov - Form 4

Security (Instr. 3)	or Exercise Price of Derivative Security		any (Month/Day/Year)	Code (Instr. 8)	Securities Acquired (A Disposed of (Instr. 3, 4, 5)	f (D)	(Month/Day/Year)		(Instr. 3 and 4)	
				Code V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amoun Numbe Shares
Employee Stock Options (Right to Buy) (1)	\$ 1.79	06/13/2012		А	100,000		06/13/2012	06/12/2022	Common Stock	100,0
Reporting Owners										

Reporting Owner Name / Address				
	Director	10% Owner	Officer	Other
Kogan Yakov C/O CLEVELAND BIOLABS, INC. 73 HIGH STREET BUFFALO, NY 14203	Х		Chief Executive Officer	
Signatures				
/s/ Leah Brownlee, Attorney-in-fact fo Kogan				
**Signature of Reporting Person			Date	
E I				

## **Explanation of Responses:**

\* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) On June 13, 2012, with the approval of the Compensation Committee, Cleveland BioLabs, Inc. issued stock options to Dr. Kogan per the 2012 Executive Compensation Plan.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.